Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Pharmaust Limited ( (AU:NUZ) ) is now available.
Neurizon Therapeutics has issued 79,330,864 fully paid ordinary shares at $0.08 per share to sophisticated and professional investors under a placement first announced in late December 2025. The company has confirmed the shares were issued without a prospectus under the Corporations Act’s cleansing provisions and that it remains compliant with its continuous disclosure and financial reporting obligations, with no excluded information outstanding, effectively clearing the way for secondary trading of the new stock and reinforcing regulatory transparency for shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease, with a strategy to accelerate patient access to effective ALS therapies and explore broader neurodegenerative applications through international collaborations and clinical programs.
Average Trading Volume: 773,723
Technical Sentiment Signal: Sell
Current Market Cap: A$64.51M
See more insights into NUZ stock on TipRanks’ Stock Analysis page.